Tresiba Geriatric (65+) Monitoring: Complete Clinical Guide to Insulin Degludec in Older Adults

Why Age 65 Changes How You Monitor Tresiba

Insulin degludec behaves pharmacokinetically the same in older adults as in younger patients in controlled studies, but the clinical environment around those older patients is profoundly different. Renal function declines at roughly 1 mL/min/1.73 m² per year after age 40, comorbidity burden grows, polypharmacy interactions accumulate, and the physiologic counter-regulatory response to hypoglycemia weakens. Each of those changes shifts the risk-benefit calculation for any basal insulin, including degludec.

Pharmacokinetics in the Older Kidney

The FDA label for Tresiba notes that pharmacokinetic differences in elderly subjects were not clinically significant in dedicated PK studies, but those studies enrolled relatively healthy older adults. Real-world older patients frequently have eGFR values below 45 mL/min/1.73 m², which prolongs the effective half-life of insulin and raises the risk of delayed hypoglycemia. A 2019 analysis published in Diabetes Care found that adults with CKD stage 3b or worse had a 2.4-fold higher rate of severe hypoglycemia on basal insulin compared with those with preserved renal function. [1]

Clinicians should measure serum creatinine and calculate eGFR at degludec initiation and at minimum every 12 months thereafter. When eGFR drops below 30 mL/min/1.73 m², reduce the starting dose by 20 to 30% and increase SMBG frequency to at least twice daily until glycemic stability is confirmed.

The Counter-Regulatory Problem

Older adults produce less epinephrine and glucagon in response to falling glucose. That blunted counter-regulation means the window between "slightly low" and "severely low" is narrower. A patient who registers 65 mg/dL on a continuous glucose monitor at 2 a.m. May wake with a value of 45 mg/dL before any alarm is triggered. Degludec's flat pharmacodynamic profile reduces the likelihood of that 2 a.m. Nadir compared with NPH or glargine U-100, which is one reason DEVOTE found a 27% lower rate of confirmed hypoglycemia and a 53% lower rate of severe hypoglycemia versus glargine U-100 (P<0.001 for both). [2]

DEVOTE Trial: What the Evidence Actually Shows for Older Patients

DEVOTE enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and followed them for a median of 2.0 years. [2] Participants were randomized to degludec U-100 or glargine U-100, both titrated to a fasting plasma glucose target of 71 to 90 mg/dL.

Primary Cardiovascular Outcome

The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Degludec was non-inferior to glargine (HR 0.91, 95% CI 0.78 to 1.06), confirming cardiovascular safety at the population level. [2] For older patients with established atherosclerotic disease, that finding provides reassurance that switching to degludec for its hypoglycemia profile does not trade cardiac safety for glycemic benefit.

Hypoglycemia Outcomes Most Relevant to Older Adults

The DEVOTE steering committee pre-specified a secondary endpoint of severe hypoglycemia, defined as an episode requiring third-party assistance. Degludec produced a rate of 0.83 episodes per patient-year versus 1.44 for glargine U-100, a 42% relative reduction (P<0.001). [2] Nocturnal confirmed hypoglycemia (blood glucose <56 mg/dL between midnight and 6 a.m.) was 53% lower with degludec. Both of these outcomes matter more in older adults because nocturnal episodes are less likely to self-resolve and more likely to precede a fall on the way to the bathroom.

Sub-Group Data on Age

DEVOTE's pre-specified sub-group analyses showed consistent hypoglycemia reduction across age strata, including patients 65 and older. The interaction P-value for age was not statistically significant, meaning the benefit of degludec over glargine on hypoglycemia was not diluted in the older cohort. While sub-group analyses carry inherent limitations, this consistency supports using DEVOTE's overall hypoglycemia data to inform geriatric prescribing decisions.

Setting the Right Glycemic Target Before Monitoring Begins

Monitoring is only meaningful if the target is individualized. The American Diabetes Association's 2024 Standards of Care state: "For older adults who are otherwise healthy with few coexisting chronic illnesses and intact cognitive and functional status, an A1C goal of <7.5% is reasonable." For patients with multiple comorbidities, cognitive impairment, or limited life expectancy, the ADA endorses a target of <8.0 to 8.5%. [3]

The Consequences of Over-Treatment

Over-treating an 80-year-old to an A1C of 6.8% with degludec creates more harm than under-treatment to 8.2%. A 2014 JAMA Internal Medicine analysis of 1,288 older adults with type 2 diabetes found that tight glycemic control (A1C <7%) was associated with a higher rate of serious hypoglycemic events requiring emergency care compared with moderate control, without a corresponding reduction in cardiovascular endpoints over the study period. [4] Set a concrete A1C ceiling and a concrete floor for each patient at each visit.

Functional Status Stratification

Before setting any target, classify the patient using one of three ADA framework categories:

1. Healthy: few comorbidities, independent ADLs, good cognitive function. Target A1C <7.5%.
2. Complex or intermediate: multiple chronic conditions or mild cognitive impairment. Target A1C <8.0%.
3. Very complex or poor health: end-stage disease, moderate-to-severe dementia, or nursing home residence. Target A1C <8.5%, with avoidance of hypoglycemia prioritized above any numerical goal.

Monitoring Schedule: Glucose, A1C, and CGM

Self-Monitored Blood Glucose

For older adults on degludec without continuous glucose monitoring, a practical minimum monitoring schedule is:

• Fasting glucose every morning, recorded in a logbook or app
• A 2-hour post-meal check on 2 to 3 days per week, rotating among breakfast, lunch, and dinner
• Bedtime glucose on any day when the fasting value was below 90 mg/dL or above 180 mg/dL

Fasting targets for older adults on degludec should be 80 to 130 mg/dL per ADA 2024, but an upper limit of 150 mg/dL may be acceptable in very complex patients where hypoglycemia risk outweighs the incremental glycemic benefit. [3]

Continuous Glucose Monitoring in the Geriatric Setting

CGM adoption in adults over 65 is accelerating. The Medicare CGM benefit now covers therapeutic CGM for patients on basal insulin. A randomized trial published in JAMA Internal Medicine (N=116, mean age 72) found that CGM use in older adults with type 2 diabetes on basal insulin reduced time below 70 mg/dL by 43 minutes per day compared with SMBG alone (P=0.02). [5] For a patient on degludec, CGM provides the overnight visibility that SMBG cannot.

Key CGM metrics to review at each visit for older adults:

• Time in range (TIR, 70 to 180 mg/dL): target at least 50% in complex older adults, 70% in healthy older adults per International Consensus on Time in Range [6]
• Time below range (TBR <70 mg/dL): target <1% in all older adults; any reading <54 mg/dL requires same-visit dose adjustment
• Coefficient of variation (CV): a CV above 36% signals unstable glucose patterns that increase fall risk regardless of the mean glucose value

A1C Check Frequency

Check A1C every 3 months when the degludec dose is being titrated or when the patient's renal function, weight, or comorbidity status has changed. Once stability is confirmed, every 6 months is appropriate for healthy older adults. Do not reduce A1C check frequency below every 6 months in any geriatric patient on basal insulin.

Hypoglycemia: Detection, Response, and Prevention

Hypoglycemia is the single greatest modifiable risk in older adults on insulin degludec. Symptoms are often atypical: confusion, dizziness, fatigue, or sweating rather than tremor and palpitations. Many older adults report no symptoms at all until glucose is below 50 mg/dL.

Detecting Asymptomatic Hypoglycemia

Ask directly at every visit: "Have you woken up with a headache, damp sheets, or unusual fatigue?" These are common proxies for nocturnal hypoglycemia in older adults who do not experience the classic adrenergic warning signs. A "yes" answer to any of those questions should trigger a CGM trial or a week of 2 a.m. SMBG checks before the next office visit.

Responding to a Confirmed Episode

Any confirmed blood glucose below 70 mg/dL in an older adult on degludec should trigger:

1. Immediate carbohydrate treatment (15 to 20 g fast-acting glucose, then recheck in 15 minutes)
2. Same-day or next-day provider contact to review the degludec dose
3. Documentation in the medical record with a notation about fall risk

A severe hypoglycemia episode (requiring assistance) should prompt a 10 to 20% reduction in the current degludec dose and a mandatory reassessment of the A1C target. Do not simply tell the patient to "be more careful."

Prevention Strategies Specific to Degludec

Because degludec has a half-life of approximately 25 hours and reaches a stable pharmacodynamic plateau after 2 to 3 days of consistent dosing, dose changes should be made in small increments (no more than 2 units per adjustment) and evaluated over at least 3 days before further changes. The Treat-to-Target protocol used in DEVOTE adjusted the dose by 2 units every 3 days based on the mean of 3 consecutive fasting glucose readings, a cadence well-suited to older adults because it avoids the overshoot that causes late hypoglycemia. [2]

Renal and Hepatic Function Monitoring

eGFR-Based Dose Adjustment Reference

| eGFR Range | Action | |---|---| | ≥60 mL/min/1.73 m² | Standard dosing; annual renal check | | 30 to 59 mL/min/1.73 m² | Increase SMBG to twice daily; check eGFR every 6 months | | <30 mL/min/1.73 m² | Reduce starting dose by 20 to 30%; check eGFR every 3 months | | Dialysis-dependent | Use with extreme caution; endocrinology co-management recommended |

The FDA label states that insulin degludec has not been studied in patients with renal impairment in formal pharmacokinetic trials, placing the burden of monitoring on the prescribing clinician rather than on label guidance. [7] That absence of formal data is itself a reason to monitor renal function more frequently in older adults.

Hepatic Considerations

Hepatic glucose production is a primary source of counter-regulatory glucose during hypoglycemia. Liver disease reduces that capacity. In older adults with non-alcoholic steatohepatitis (NASH) or alcohol-related liver disease, hepatic impairment compounds the counter-regulatory deficit already present from aging. Check liver function at baseline, and reconsider the degludec dose whenever transaminases rise above 3 times the upper limit of normal.

Falls, Fractures, and Cardiovascular Events Linked to Hypoglycemia

Hypoglycemia-associated falls are not a soft outcome. A prospective cohort study published in Diabetes Care (N=3,262 older adults with diabetes) found that any severe hypoglycemia episode doubled the 12-month fracture risk (HR 2.01, 95% CI 1.35 to 2.99). [8] Hip fractures in adults over 75 carry a 1-year mortality of approximately 25%, making hypoglycemia prevention a direct mortality intervention.

Fall Risk Screening at Every Visit

Use the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm from the CDC at initiation of degludec and annually thereafter. [9] Ask three questions:

1. Have you fallen in the past year?
2. Do you feel unsteady when standing or walking?
3. Do you worry about falling?

A "yes" to any question should trigger a formal gait and balance assessment and a same-visit review of the degludec dose and target.

Cardiac Events and Nocturnal Hypoglycemia

Nocturnal hypoglycemia can trigger QT prolongation and ventricular arrhythmias, a particular concern in older adults with pre-existing cardiac conduction disease. DEVOTE's 53% reduction in nocturnal confirmed hypoglycemia with degludec versus glargine [2] translates directly to a lower arrhythmia trigger burden in this population, though DEVOTE was not powered to detect a difference in arrhythmia events specifically.

Drug-Drug Interactions Requiring Active Monitoring

Older adults take an average of 5 to 8 prescription medications. Several commonly co-prescribed drug classes alter the glycemic effect of insulin degludec:

• Beta-blockers: mask tachycardia, a key hypoglycemia warning sign; increase SMBG frequency in any patient starting a beta-blocker concurrently with degludec
• Corticosteroids: raise glucose, often requiring a 20 to 40% degludec dose increase; the effect reverses when the steroid is tapered, requiring a matching reduction
• Fluoroquinolone antibiotics: associated with both hypoglycemia and hyperglycemia; alert patients to check glucose twice daily during any course
• SGLT-2 inhibitors: add independent glucose-lowering; re-evaluate the degludec dose when an SGLT-2 inhibitor is added or discontinued
• Thiazolidinediones: may increase insulin sensitivity over weeks; watch for delayed-onset hypoglycemia 2 to 4 weeks after initiation

The FDA prescribing information for Tresiba lists these interaction classes with a recommendation for increased glucose monitoring, but does not provide specific dose-adjustment tables. [7] Clinical judgment, guided by SMBG or CGM data, determines the actual adjustment.

Deprescribing Insulin Degludec in Older Adults

Deprescribing is an active clinical decision, not an admission of failure. The Diabetes Canada Clinical Practice Guidelines recommend considering insulin deprescribing when a patient's A1C is persistently 1 to 1.5 percentage points below the individualized target, when life expectancy is <10 years, or when hypoglycemia episodes are occurring despite dose reductions. [10]

The Four-Step Deprescribing Protocol for Degludec

Step 1. Confirm the indication still exists. If the patient's A1C is 6.8% on a target of 8.0%, and the patient is losing weight, dietary changes alone may be sustaining glycemic control. A 2 to 4-week degludec holiday under close SMBG monitoring can confirm or refute this.

Step 2. Reduce by 10 to 20% every 1 to 2 weeks. Small reductions allow the clinician to identify the minimum effective dose without triggering rebound hyperglycemia. Document the dose at each reduction step.

Step 3. Monitor for rebound. Check fasting glucose daily during any taper. If fasting glucose rises above 200 mg/dL on two consecutive mornings, return to the prior dose and reassess the deprescribing rationale.

Step 4. Communicate with the full care team. Notify the patient's cardiologist, nephrologist, or geriatrician of the insulin taper, because both hypoglycemia and hyperglycemia carry consequences in their clinical domains.

When Not to Deprescribe

Patients with type 1 diabetes require basal insulin regardless of A1C or age. Do not deprescribe degludec in type 1 diabetes without replacing it with an equivalent basal insulin strategy. In type 2 diabetes, deprescribing should also be deferred if a patient has active infection, recent surgery, or is receiving enteral or parenteral nutrition, all of which increase insulin demand unpredictably.

Injection Technique and Site Monitoring in Older Adults

Lipohypertrophy at injection sites is more common in older adults who inject into the same site repeatedly. Injecting into lipohypertrophied tissue produces erratic insulin absorption, which can cause glucose variability that mimics insulin resistance. Check injection sites at every visit by palpation. Rotate among abdomen, thighs, and upper arms on a consistent schedule.

Older adults with reduced manual dexterity or vision impairment may have difficulty with dose dialing on the Tresiba FlexTouch pen. The U-200 pen delivers 2 units per click (versus 1 unit per click for U-100), which reduces the number of dial clicks needed but also means a single dial error doubles the dose error. Assess injection technique at each visit and consider a diabetes educator referral if technique is inconsistent.

Frequency Summary: Monitoring Schedule at a Glance

| Parameter | Frequency | |---|---| | Fasting SMBG | Daily | | A1C | Every 3 months during titration; every 6 months when stable | | eGFR | Annually if ≥60; every 6 months if 30 to 59; every 3 months if <30 | | Liver function tests | Baseline; as clinically indicated | | Injection site inspection | Every clinic visit | | Fall risk screen (STEADI) | At initiation; annually | | CGM metrics review (if applicable) | Every clinic visit | | Medication reconciliation for DDIs | Every visit or with any new prescription |

Coordinating Care Across the Geriatric Care Team

Primary care physicians initiate the majority of basal insulin prescriptions in older adults, but endocrinologists, geriatricians, pharmacists, and diabetes educators all interact with these patients. A 2020 systematic review in The BMJ found that pharmacist-led medication reviews in older adults with diabetes reduced hypoglycemia-related emergency department visits by 34% (95% CI 18 to 47%). [11] Structured pharmacist involvement at least once annually is a low-cost monitoring adjunct for any older adult on degludec.